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Despite some efforts in the adjuvant treatment of high-risk
melanoma (stageII/III) (Kirkwood et al, 1996; Grob et al, 1998;
Pehamberger et al, 1998), little has changed in the management of
advanced metastatic disease, stage IV as defined by the American
Joint Committee on Cancer (AJCC) (Buzaid et al, 1997). The
median survival times of affected patients reported in various
studies differ, but the most recent randomized trials arrive at
survival times between 6 and 9 months (Chapman et al, 1999). In
all studies up to the present survival times of more that 3 years are
very rare. 
If a ‘golden standard’ for the treatment of advanced melanoma
existed, it would be dacarbazine (DTIC), but unfortunately DTIC
is only able to produce tumour responses in 12% of treated
patients and the impact on survival time remains unclear (Hill 
et al, 1984). Temozolomide, a novel oral alkylating agent with a
broad spectrum of antitumor activity and relatively little toxicity,
was recently shown to be equally effective as DTIC in the treat-
ment of advanced metastatic melanoma (Middleton et al, 2000). 
Complex combinations of cytotoxic drugs with biological
response modifiers, such as interferon a (IFNa) and interleukin 2
(IL-2), demonstrated encouraging results in achieving long-lasting
tumour responses (Legha et al, 1998; Richards et al, 1999). A rela-
tively large number (about 10%) of patients with lasting complete
remissions will survive for many years. However, most results
were drawn from single-institutional phase II-trials with patients
who were probably selected (Legha et al, 1998; Richards et al,
1999). Recently, a prospective-randomized trial compared treat-
ment with cisplatin, DTIC and tamoxifen only to a combination of
these substances with IL-2 and IFNa (Rosenberg et al, 1999).
Although toxicity was increased, the addition of immunotherapy
to chemotherapy did not lead to an improvement in either the
response rate or median survival time. The authors concluded
that chemoimmunotherapy cannot be recommended until well-
designed, prospective-randomized protocols have been developed
(Rosenberg et al, 1999). 
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Summary In several phase II-trials encouraging tumour responses rates in advanced metastatic melanoma (stage IV; AJCC-classification)
have been reported for the application of biochemotherapy containing interleukin 2. This study was designed to compare the efficacy of
therapy with dacarbazine (DTIC) and interferon a (IFN-a) only to that of therapy with DTIC and IFN-a with the addition of interleukin 2 (IL-2)
in terms of the overall survival time and rate of objective remissions and to provide an elaborated toxicity profile for both types of therapy. 290
patients were randomized to receive either DTIC (850 mg/m2 every 28 days) plus IFN-a2a/b (3 MIU/m2, twice on day 1, once daily from days
2 to 5; 5 MIU/m2 3 times a week from week 2 to 4) with or without IL-2 (4.5 MIU/m2 for 3 hours i.v. on day 3; 9.0 MIU/m2 i.v. day 3/4; 4.5 MIU/m2
s.c. days 4 to 7). The treatment plan required at least 2 treatment cycles (8 weeks of therapy) for every patient. Of 290 randomized patients
281 were eligible for an intention-to-treat analysis. There was no difference in terms of survival time from treatment onset between the two
arms (median 11.0 months each). In 273 patients treated according to protocol tumour response was assessable. The response rates did not
differ between both arms (P = 0.87) with 18.0% objective responses (9.7% PR; 8.3% CR) for DTIC plus IFN-a as compared to 16.1% (8.8%
PR; 7.3% CR) for DTIC, IFN-a and IL-2. Treatment cessation due to adverse reactions was significantly more common in patients receiving
IL-2 (13.9%) than in patients receiving DTIC/IFN-a only (5.6%). In conclusion, there was neither a difference in survival time nor in tumour
response rates when IL-2, applied according to the combined intravenous and subcutaneous schedule used for this study, was added to DTIC
and IFN-a. However, toxicity was increased in melanoma patients treated with IL-2. Further phase III trials with continuous infusion and higher
dosages must be performed before any final conclusions can be drawn on the potential usefulness of IL-2 in biochemotherapy of advanced
melanoma. © 2001 Cancer Research Campaign http://www.bjcancer.com
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The rationale of the current study was to compare the efficacy
and tolerability of a DTIC and IFNa combination alone to the
same schedule with the addition of IL-2. At the time the study
design was being developed (1993/1994) a meta-analysis (data not
published) revealed a 29% remission rate for patients treated in
phase II- and phase III-trials using DTIC and IFNa combined
(Falkson et al, 1991; Punt, 1998). These results lead to the decision
to use this combination as a kind of standard of care for advanced
melanoma, despite controversial discussions and results published
within this time period (Falkson et al, 1998). 
To our knowledge this study represents the first randomized
multi-centre trial on the effect of IL-2 as a supplement to conven-
tional therapy. Therefore, the primary objectives were to evaluate
differences in the efficacy in terms of objective tumour responses
and overall survival time as well as in the tolerability of the 2 
regimens. 
PATIENTS AND METHODS 
Patient selection 
Patients between 18 and 70 years of age with advanced metastatic
melanoma (according to stage IV; AJCC-classification) (Buzaid
et al, 1997) were eligible for the study. Prerequisites for inclusion
were a Karnofsky performance status of at least 70%, an expected
remaining survival time of at least 3 months, bi-dimensionally
measurable disease (bone metastasis and/or efflusions were not
considered to be measurable) and the absence of other malignan-
cies. Patients with brain metastasis and/or ocular melanoma were
not included. Patients had to be treatment- naive (with the excep-
tion of surgical interventions) in stage IV to be included, but
previous chemo-, interferon- and/or IL-2 treatment in an adjuvant
setting at least 4 weeks prior randomization was not an exclusion
criterion. Adequate blood counts (leukocytes >3000/mm3; throm-
bocytes > 100 000/mm3; haemoglobin level >10 g dl–1), renal
(creatinine level < 2.0 times the upper limit of normal (ULN) and
hepatic functions (bilirubin level < 3 times ULN; AST <3 times
ULN) were also required. Patients with active infections, severe
underlying diseases (other than metastatic melanoma), manifest
thyroid dysfunction, insulin-dependent diabetes mellitus or diseases
requiring systemic application of corticosteroids (i.e. autoimmune
disorders) were not enrolled. Patients suffering from severe heart
diseases including arrhythmia also had to be excluded. Women who
were pregnant or breastfeeding were ineligible for the study. 
Local ethical review committees of participating centres approved
the study. All patients received written information about the
purpose of the trial and potential adverse reactions to the study
medication. All patients participating in the study gave written
informed consent. 
Treatment schedule 
Patients were randomized at a central office to receive either DTIC
and IFNa2a/b (arm A) or DTIC, IFN- a2a/b plus IL-2 (arm B). 
Arm A 
On day one 850 mg/m2 DTIC was administered intravenously
(i.v.). Approximately 1 h prior and 1 h following i.v. administra-
tion of DTIC 3 MIU/m2 IFN-a2a/b were self-administered subcu-
taneously (s.c.) by the patient who had previously been instructed
in self-injection. From day 2 to 5 patients received 3 MIU/m2 s.c.
once daily in the evening. In weeks 2 to 4 IFN-a2a/b was applied
3 times a week in a dose of 3 MIU/m2 s.c. This 4-week regimen
was repeated at least twice. To reduce toxicity, serotonin antago-
nists (i.e. ondansetron, tropisetron, granisetron) were given i.v.
prior to chemotherapy. Antipyretics (i.e. paracetamol, metamizol)
were applied when necessary at conventional dose levels to over-
come cytokine-induced flu-like symptoms. 
Arm B 
The same basic medication (DTIC; IFN a2a/b) as in arm A was
applied. In addition, IL-2 was administered over different routes
(i.v., s.c.) and in varying doses. In the first week IL-2-infusions
were started at day 3 with a 3-hour administration of 4.5 MIU/m2
followed by a continuous 24-hour i.v. application of 9.0 MIU/m2
IL-2. From day 4 to 7 patients applied self-injections of 4.5 MIU/
m2 IL-2 subcutaneously in the evening. The cumulative dose of
IL-2 was 31.5 MIU/m2 per treatment cycle. The side medication to
overcome adverse reactions was the same as in arm A, but some-
times had to be administered in higher dosages. 
Pretreatment evaluation 
All patients had to provide a complete medical history and be
given a thorough physical examination. The following blood tests
were performed routinely: blood cell counts, liver, renal and
thyroid function tests, electrolytes and serum glucose. These tests
were repeated 3 times in week 1 and once a week from weeks 2 to
4. Individual aberrations from these guidelines were tolerated. 
In the initial phase of the study an electrocardiogram (ECG) was
performed on every patient, later on this procedure was recom-
mended for cardiac risk patients only. 
To assess treatment response at least a chest X-ray, an abdom-
inal ultrasound, a CT scan or MRI of the brain and bone scintig-
raphy were required. Most of the randomized patients also
received CT scans of the thorax and abdomen. 
Treatment response re-evaluation 
After 8 weeks (2 cycles) of treatment patients were examined by
the same physical, biochemical and technical means as in the pre-
treatment phase. Patients were allowed to continue on protocol as
long as the disease was not progressive and blood parameters did
not indicate treatment cessation. 
Tumour responses (PD, progressive disease; SD, stable disease;
PR, partial remission; CR, complete remission) and the severity of
adverse events (AEs) were assessed using the criteria of the World
Health Organization (WHO). 
Patients with non-progressive disease were re-evaluated after
every 2 additional cycles of chemoimmunotherapy (following
cycle number 4 and 6). 
Participating centres were screened by an external monitoring
process for the accuracy of submitted patient data, demographics
and tumour responses. 
Statistics 
The primary objective of this study was to compare the overall
survival time of patients in arm A and arm B. Therefore, an intent-
to-treat analysis (all randomized patients) and furthermore a ‘per
protocol analysis’ by considering only eligible and treated patients
was performed. The sample size was calculated on the basis of an1038 A Hauschild et al 
British Journal of Cancer (2001) 84(8), 1036–1042 © 2001 Cancer Research Campaign
expected difference in survival of 3 months (6 months versus 9
months) with 80% power at a 5% significance level. To calculate
overall survival in the 2 treatment arms Kaplan–Meier estimates
were generated. Survival curves were compared by means of a log-
rank test. Another primary goal of the study was to compare the
remission rates achieved by the 2 treatment schedules. 
All patients were observed until death or the end of the observa-
tion period (November 1999). Data on the exact date and cause of
death were recorded. Survival time was calculated from the onset
of treatment. 
RESULTS 
Patients 
Between October 1994 and April 1998, 290 patients were
recruited at 24 centres in Germany and Switzerland (see
Appendix). In 7 patients a lost-for-follow-up despite intensive
endeavour and in 2 patients a revision of diagnosis (metastatic
colorectal cancer instead of metastatic melanoma) became
apparent during the external monitoring process in participating
centres at the end of the study 281 remaining patients could be
evaluated for response and for an intent-to-treat analysis, respec-
tively (Figure 1). 
Of these patients 144 were randomized to receive DTIC and
IFNa (arm A) and 137 to receive DTIC, IFNa and IL-2 (arm B). 
8 patients had to be counted as protocol violators, either because
they did not receive treatment in strict accordance with the given
protocol or because of violations of the inclusion/exclusion
criteria. The reasons for exclusion were previous systemic treat-
ment in stage IV, brain metastasis or non-measurable metastatic
sites. 
Thus, 273 remaining patients were evaluable for a per-protocol
analysis. Of these, 140 patients received DTIC and IFNa (arm A),
whereas 133 patients received DTIC, IFNa and IL-2 (arm B). 
Patient demographics are presented in Table 1. Analysis of this
data revealed no major differences regarding relevant prognostic
factors in gender, metastatic sites or the number of metastatic
affected organs at baseline between the 2 treatment arms (Pearson
chi-square test; P value >0.05). 
Survival analysis 
In the intent-to-treat analysis (ITT) we were able to include
survival data on 220 patients (78.3%), who had already died and of
53 patients (18.9%), who were still living at the last monitoring
date (censored data). In addition, we included survival data of 8
protocol violators (2.8%). 
The overall median survival time was 11 months for arm A
patients (DTIC + IFNa) (95% confidence interval: 9.4–12.6) 
as well as for arm B patients (DTIC + IFNa + IL-2) (95% 
CI: 8.9–13.2, P = 0.52). The ITT survival curves are shown in
Figure 2. There was no statistically significant difference in overall
survival between the groups (P = 0.53). 
A further statistical evaluation including only the data of patients
who were treated according to protocol (‘per-protocol analysis’) also
showed no statistical significant difference (P = 0.45) in survival
time between the two study arms (arm A: median 11 months, 
95% confidence interval: 9.1–12.8 arm B: median 12 months, 95%
confidence interval: 9.9–14.1). 
Tumour responses 
The ITT analysis of best tumour responses was based on data from
281 patients (144 patients in arm A and 137 patients in arm B).
Table 2 shows that tumour responses were almost equally distrib-
uted between the 2 treatment groups. 12 melanoma patients (8.3%)
receiving arm A treatment (DTIC + IFNa) compared to 10 patients
(7.3%) receiving arm B treatment (DTIC + IFNa + IL-2) demon-
strated a complete remission (CR) of all measurable metastatic
sites. Furthermore, in a total of 26 patients (14 in arm A, 9.7%
versus 12 in arm B, 8.8%) partial responses (PR) could be docu-
mented. Thus, the overall response rate (CR + PR) for arm A was
18.0% and for arm B 16.1%. The disease remained stable (SD) in
33 patients (22.9%) receiving DTIC and IFN-a and in 32 patients
(23.4%) receiving supplementary IL-2 treatment. 58.3% (arm A)
and 60.6% (arm B) of the patients respectively suffered from
progressive disease (PD) (Table 2). No statistically significant
differences in terms of tumour response were detectable between
the 2 groups (P = 0.87). 
Patients randomized
(n = 290)
Patients eligible for
intention-to-treat analysis (n = 281)
Lost to follow-up after
randomization (n = 7)
Patients with diagnosis
revision (colorectal cancer) (n = 2)
Arm B (DTIC + IFNa+IL-2)
(n = 137)
Arm A (DTIC + IFNa)
(n = 144)
Per protocol
(n = 140)
Withdrawn
(n = 4)
Per protocol
(n = 133)
Withdrawn
(n = 4)
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Figure 2 Kaplan–Meier survival plot of 281 patients randomized based on
intent to treat. Median survival time for patients treated with DTIC plus IFNa
was 11 months (95% CI: 9.4–12.6 months, continuous line) and for patients
treated with DTIC plus IFNa and IL-2 also 11 months (95% confidence
interval: 8.9–13.2 months, dotted line, P = 0.52)Toxicity 
Potentially, all patients treated per protocol could be assessed in
regard to an eventual discontinuation of treatment. However, only
217 patients could be evaluated for whom a detailed analysis of
side effects according to the WHO-grading system for adverse
events had been performed. For 63 of the patients treated per
protocol no detailed WHO-grading for toxicity was reported. This
subgroup of patients was evenly distributed between the 2 treat-
ment arms. 
In general, both treatment modalities were well tolerated and
most of the adverse events were only mild or moderate (WHO
grades I/II). The most common side effects were, as expected, flu-
like symptoms such as fever, chills or fatigue. These reactions
were more frequently observed in the treatment group receiving
IL-2 (Table 3). 
Patients in arm B suffered more often from nausea and
vomiting, somnolence, diarrhoea, dyspnoea, pruritic skin rash and
alopecia. Grade 3 and 4 toxicities were observed only occasionally
(in 1 to 2% of the patients) and were reversible after discontinua-
tion of the study drug. No life-threatening adverse events were
reported. 
Haematological toxicity in the form of mild myelosuppression
was frequently observed, but grade III reactions (up to 10%) and
grade IV toxicity (up to 3%) rarely occurred (Table 3). Haemato-
logical toxicity was reversible in all cases. 
Differences in the frequency and severity of haematological
adverse events between the 2 treatment groups were not
DTIC + IFNa +/– IL-2 1039
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Table 1 Patient demographics in 281 evaluable melanoma patients 
DTIC + IFNa DTIC + IFNa + IL-2
No. of pts. % No. of pts. %  P value 
Gender 144 51.2 137 48.8 0.66 
Male 95 66.0 87 63.5 
Female 49 34.0 50 36.5 
Metastatic sites 141 50.9 136 49.1 0.29 
Limited diseasea 68 48.2 57 41.9 
Extensive diseaseb 73 51.8 79 58.1 
Number of metastatic organs involved 141 50.9 136 49.1 0.62 
1 39 27.7 45 33.1 
2 55 39.0 49 36.0 
3+ 47 33.3 42 30.9 
aSkin and/or lymph node and/or lung involvement. bLiver and/or brain and/or bone involvement. 
Table 2 Response rates among 281 assessable patients 
Arm A Arm B 
Response DTIC + IFNa DTIC + IFNa + IL-2 
n % n % 
Complete remission (CR) 12 8.3 10 7.3 
Partial remission (PR) 14 9.7 12 8.8 
Stable disease (SD) 33 22.9 32 23.4 
Progressive disease (PD) 84 58.3 83 60.6 
Overall response rate 
(CR + PR) 26 18.1 22 16.1 
Non-progressive patients 
(CR + PR + SD) 59 41.0 54 39.4 
Table 3 Adverse reactions observed among 217 patients evaluated for toxicity 
Arm A: DTIC + IFNa Arm B: DTIC + IFNa + IL-2 
Adverse event WHO-grade (%) WHO-grade (%) 
I/II III IV I/II III IV 
Anaemia 26 1 0 36 1 3 
Leucopenia 38 10 0 41 3 3 
Neutropenia 32 6 0 28 1 3 
Thrombocytopenia 21 4 2 19 3 3 
Elevated liver enzymes 26 3 1 31 4 1 
Elevated creatinine 3 0 0 6 2 0 
Fever/chills 52 2 1 75 9 2 
Nausea/vomiting 44 8 0 55 14 2 
Somnolence 4 1 0 20 0 0 
Obstipation 7 0 0 9 0 0 
Diarrhoea 12 1 0 20 3 0 
Dyspnoea 4 0 1 9 2 0 
Skin rash 10 0 0 32 0 0 
Alopecia 13 1 0 22 1 0 1040 A Hauschild et al 
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detectable. However, treatment had to be discontinued because of
side effects more often for patients receiving supplementary IL-2
(arm B) than for those receiving only DTIC and IFNa (P = 0.043)
and this difference remained constant for all of the documented
side effects. In arm B treatment of 19 (13.9%) patients had to be
discontinued due to side effects of biochemotherapy whereas these
side effects were severe enough to necessitate discontinuation in
only 8 (5.6%) of the arm A patients. In addition, a small number 
of patients (arm A, n = 1, 0.7% versus arm B, n = 3; 2.2%) refused
further treatment for personal reasons, not because they suf-
fered from significant non-haematological or haematological side
effects. 
In the arm A patient population 53.9% received 1 to 3 treatment
cycles, 27.0% 4 to 6 cycles and 19.1% more than 6 cycles of the
given treatment. In contrast, the number of applied treatment
cycles in the patient population treated with IL-2 (arm B) was
significantly lower (P = 0.028). 63% of patients received 1 to 3,
28.9% 4 to 6 and 8.1% more than 6 treatment cycles. 
One patient committed suicide in the face of increasing dis-
ability due to progressive melanoma causing paraplegia. This was
not considered to be related to the study drugs. 
DISCUSSION 
In this prospective-randomized multicentre phase III-trial we
compared survival data, tumour responses and the toxicity profiles
in patients receiving 2 treatment schedules. One treatment group
(arm A) received DTIC and IFNa, a second group (arm B) re-
ceived the same plus IL-2. To our knowledge, this study represents
the first randomized trial on the efficacy of a biochemotherapy
regimen with or without the addition of IL-2. 
Up to the present, IL-2 has either been applied as a monotherapy
in several single-institutional studies with remission rates of about
15 to 20% (Atkins et al, 1999) or as an adjunct to chemotherapy
(i.e. DTIC) (Dummer et al, 1995) or to IFNa (Keilholz et al,
1998). In the last years, several phase II-trials have focused on
biochemotherapy consisting of a combination of several cytotoxic
substances with IFNa and IL-2 (Legha et al, 1998; Proebstle et al,
1998; Richards et al, 1999; Sertoli et al, 1999). Legha and co-
workers reported on encouraging tumour responses (21% CR,
43% PR) achieved with biochemotherapy in advanced metastatic
melanoma patients (Legha et al, 1998). They used cisplatin,
vinblastine, DTIC plus IL-2 (i.v. administration) and IFNa (s.c.
administration). Richards and colleagues reported on quite similar
results (55% response rate) with a combination of cisplatin, DTIC
and carmustine with i.v. IL-2 and s.c. IFNa in 83 metastatic
melanoma patients. Both authors recommended performing a
randomized trial to establish the value of biochemotherapy for
melanoma treatment in the future (Legha et al, 1998; Richards 
et al, 1999). Recently, Rosenberg and co-workers (Rosenberg et al,
1999) published data on a prospective-randomized trial using
chemotherapy with cisplatin, dacarbazine and tamoxifen alone or
in combination with IL-2 and IFNa2b. 102 patients were enrolled
in this National Cancer Institute study. However, the investigators
discovered that the addition of immunotherapy to chemotherapy
increased toxicity, but did not enhance survival. Despite the better
response rate for patients who had received biochemotherapy
(44% versus 27%), the survival rate was better for patients re-
ceiving chemotherapy only (15.8 months versus 10.7 months).
Rosenberg and colleagues concluded that biochemotherapy cannot
be recommended until well-designed, prospective protocols have
demonstrated the benefits of this treatment strategy (Rosenberg
et al, 1999). Interestingly, no randomized study on biochem-
otherapy published up to now has focused on the addition of IL-2
as the sole variable despite recommendations in the literature
(Keilholz, 1995). 
Our study could demonstrate neither an increase in response
rates (CR/PR) nor a prolongation of the survival time when IL-2
was added to DTIC and IFNa. The response rate for DTIC and
IFNa without IL-2 (18.0%) corresponds to that reported in previ-
ously published phase III trials (Falkson et al, 1998). Surprisingly,
we failed to demonstrate an expected higher rate of responses with
the addition of IL-2 (16.2%). One explanation for these findings
might be that IL-2 is inactive in this setting. The cumulative dose
of IL-2 in our study (31.5 MIU/m2) is low compared to high-dose
schedules used in other trials (Keilholz et al, 1998; Legha et al,
1998; Richards et al, 1999). Furthermore, we used an IL-2 admin-
istration scheme adapted from the ‘decrescendo schedule’ intro-
duced by Keilholz and co-workers (Keilholz et al, 1997). In the
US-trials continuous infusions with constant doses of IL-2 were
preferred (Legha et al, 1998; Richards et al, 1999; Rosenberg et al,
1999). In our study, IL-2 was administered intravenously on days 3
and 4 only, on the subsequent days the subcutaneous route of
administration was chosen to allow patients self-administration of
IL-2 at home. Although efficacy of subcutaneous IL-2 was demon-
strated in several combination studies with chemotherapy and/or
IFNa (Atzpodien et al, 1990; Hoffmann et al, 1998; Kashani-Sabet
et al, 1999), data on the activity of IL-2 applied subcutaneously as
a monotherapy are limited (Atzpodien et al, 1990; Schomburg 
et al, 1992). 
Dreno and co-workers (Dreno et al, 1995) reported on a quite
similar chemoimmunotherapy scheme comparable to our study.
They observed 2 complete and 3 partial responders (response rate:
26.2%) among 19 metastatic melanoma patients. All patients
received DTIC, IFNa2a and subcutaneous IL-2 in an outpatient
setting (Dreno et al, 1995). 
In regard to the toxicity profile significant differences between
the treatment groups with or without IL-2 application were docu-
mented in our study. However, we have to consider that most of
the adverse reactions were grade I and II toxicities while grade III
and IV side effects occurred infrequently. Thus, it was surprising
that in the population of patients receiving IL-2 treatment discon-
tinuation was documented in 13.9% of affected patients in contrast
to 5.6% of the patients who received no IL-2. We have to carefully
consider the possibility that the higher rate of treatment discontin-
uation and the lower number of treatment cycles carried out in
patients receiving IL-2 may have been due to the lack of experi-
ence in applying and dealing with the side effects of IL-2 in some
of the centres participating in this study. To avoid these problems,
the Dermatologic Cooperative Oncology Group (DeCOG) offered
training programmes (‘management of adverse reactions’) for
participating centres during the whole study period. In general, the
toxicity profile for DTIC and IFNa with or without IL-2 turned out
as was expected. The study medication was well tolerated by most
patients in both arms. The majority of patients received more than
90% of the scheduled dose of both cytokines. Life-threatening
adverse reactions related to therapy were not observed. 
In conclusion, this study was not able to demonstrate that the
addition of IL-2 to DTIC and IFNa resulted in an increased
response rate or a longer overall survival time. Interestingly, the
overall survival time of our entire collective with a median of 11
months was quite good in comparison with other results reported
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in the literature. The toxicity of both regimens was in general low
to moderate. However, significantly more side effects and treat-
ment discontinuations were observed in the patient population
receiving IL-2. Consequently, it still seems questionable that IL-2
regimens with moderate dosages improve biochemotherapy sched-
ules for metastatic melanoma. The benefits of continuous high-
dose infusions of IL-2 in this context still have to be determined.
The European Organisation for Research and Treatment of Cancer
(EORTC) has designed a study in order to test the high-dose
decrescendo schedule and results will be available soon. 
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